Paper72276
Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.
Brackmann HH and 1 other. Lancet, 1977. Cited by 231 papers, by iCite.
Cite this record
ConductScience Library. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Papers, record 72276. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/72276
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Factor VII | Major topic |
| Hemophilia A | Major topic |
| Adult | |
| Factor IX | |
| Factor VIII | |
| Hemorrhage | |
| Humans | |
| Infusions, Parenteral | |
| Male | |
| Time Factors |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42307860 | Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab. | BioDrugs | 2026 | https://conductscience.org/library/papers/42307860 | PubMed |
| 39583653 | Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses. | Ther Adv Hematol | 2024 | https://conductscience.org/library/papers/39583653 | PubMed |
| 36915910 | Adeno-associated virus-vectored delivery of HIV biologics: the promise of a "single-shot" functional cure for HIV infection. | J Virus Erad | 2023 | https://conductscience.org/library/papers/36915910 | PubMed |
| 36882773 | Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review. | Orphanet J Rare Dis | 2023 | https://conductscience.org/library/papers/36882773 | PubMed |
| 36377659 | Until programmed death do us tolerant. | J Clin Invest | 2022 | https://conductscience.org/library/papers/36377659 | PubMed |
| 36107620 | Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. | J Clin Invest | 2022 | https://conductscience.org/library/papers/36107620 | PubMed |
| 35793465 | Immune complications and their management in inherited and acquired bleeding disorders. | Blood | 2022 | https://conductscience.org/library/papers/35793465 | PubMed |
| 34168126 | Haemophilia. | Nat Rev Dis Primers | 2021 | https://conductscience.org/library/papers/34168126 | PubMed |
| 32717751 | Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors. | Hamostaseologie | 2020 | https://conductscience.org/library/papers/32717751 | PubMed |
| 32425925 | Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A. | Front Immunol | 2020 | https://conductscience.org/library/papers/32425925 | PubMed |
| 32373126 | Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells. | Front Immunol | 2020 | https://conductscience.org/library/papers/32373126 | PubMed |
| 32351497 | The Immune Response to the fVIII Gene Therapy in Preclinical Models. | Front Immunol | 2020 | https://conductscience.org/library/papers/32351497 | PubMed |
| 31454152 | The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain. | J Thromb Haemost | 2020 | https://conductscience.org/library/papers/31454152 | PubMed |
| 30705923 | Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. | Mol Ther Methods Clin Dev | 2019 | https://conductscience.org/library/papers/30705923 | PubMed |
| 30411401 | Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. | Eur J Haematol | 2019 | https://conductscience.org/library/papers/30411401 | PubMed |
| 29392598 | The impact of extended half-life versus conventional factor product on hemophilia caregiver burden. | Qual Life Res | 2018 | https://conductscience.org/library/papers/29392598 | PubMed |
| 27445481 | Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A. | Ther Clin Risk Manag | 2016 | https://conductscience.org/library/papers/27445481 | PubMed |
| 27440064 | Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. | Oncologist | 2016 | https://conductscience.org/library/papers/27440064 | PubMed |
| 27061380 | Gene therapy for immune tolerance induction in hemophilia with inhibitors. | J Thromb Haemost | 2016 | https://conductscience.org/library/papers/27061380 | PubMed |
| 26770953 | Immune tolerance induction in patients with severe hemophilia A with inhibitors. | Blood Res | 2015 | https://conductscience.org/library/papers/26770953 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/72276
GET https://conductscience.org/api/papers/v1/72276/cited_by?page=2